OKYO Pharma Ltd

Share Issue/Capital Change • Jul 31, 2020

National Storage Mechanism | Additional information

RNS Number : 8148U

Okyo Pharma Ltd

31 July 2020

FOR RELEASE AT 4.30PM

31 July 2020

OKYO Pharma Limited

("OKYO" or the "Company")

Upcoming Presentation

OKYO, the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce that Kunwar Shailubhai, Ph.D., the Company's CEO, will share insight into OKYO's development pipeline and upcoming milestones during an investor webinar, hosted by RedChip Companies, on Sunday, August 2, 2020. A live Q&A session with Dr. Shailubhai will follow the presentation. A link to a recording of the presentation will be provided on Monday morning via RNS Reach.

About OKYO

OKYO Pharma Limited (LSE: OKYO) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.

Enquiries:

OKYO Pharma Limited	Willy Simon	+44 (0)20 7495 2379
Optiva Securities Limited	Robert Emmet	+ 44 (0)20 3981 4173

For further information, please visit the Company's website at www.okyopharma.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

NRAUASORRBUBOAR